Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 07:09:53 +0200Fri, 12 Jul 2024 15:27:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Prevenar 20 (previously Apexxnar), Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vaccines, PIP number: P/0246/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002330-pip01-18-m03Opinion/decision on a Paediatric investigation plan (PIP): Prevenar 20 (previously Apexxnar), Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vaccines, PIP number: P/0246/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002330-pip01-18-m03Fri, 12 Jul 2024 15:27:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 8, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-20-previously-apexxnarHuman medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 8, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-20-previously-apexxnarFri, 26 Apr 2024 17:54:00 +0200Human medicinePrevenar 20 : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5451-en.pdfPrevenar 20 : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5451-en.pdfHuman medicine